High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of Hetrombopag plus high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).
Epistemonikos ID: 25443cd38fccec2dbf14ab6ff836c46cf498f2f5
First added on: May 15, 2024